AstraZeneca’s Ultomiris Nears EU Green Light For NMOSD
After Positive CHMP Opinion
Executive Summary
The UK major’s long-acting C5 inhibitor is nearing EU approval for the debilitating rare disease as the company gears up for emerging competition and loss of exclusivity for its older drug Soliris.